Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × nintedanib × Other solid neoplasm × Clear all

Phase

Phase 1 3 Phase 2 2 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Other solid neoplasm 1

Conditions

Interventions

pembrolizumab 3 Pemetrexed 2 Drug Therapy 2 Cisplatin 2 toripalimab 1 tislelizumab 1 spartalizumab 1 sintilimab 1 penpulimab 1 nintedanib 1 camrelizumab 1 balstilimab 1 atezolizumab 1 anlotinib 1 Vincristine 1 Topotecan 1 Sentinel Lymph Node Biopsy 1 Platinum Compounds 1 Melphalan 1 Inosine 1 Injections 1 Indocyanine Green 1 Immunotherapy 1 Hyperthermia, Induced 1 Etoposide 1 Cryotherapy 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01907100 2019-03-18

Nintedanib (BIBF 1120) in Mesothelioma

Boehringer Ingelheim

Phase 2/3 Terminated

545 enrolled 15 charts

Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡